))
Biosimilars’ Good News for Patients
Archived series ("iTunes Redirect" status)
Replaced by: DIA: Driving Insights to Action
When?
This feed was archived on December 27, 2017 02:48 (
Why? iTunes Redirect status. The feed contained an iTunes new feed tag.
What now? If you were subscribed to this series when it was replaced, you will now be subscribed to the replacement series. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 188290863 series 1219012
Content provided by DIA: Driving Insights to Action. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DIA: Driving Insights to Action or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Because they require no R&D investment, biosimilars – nearly identical copies of a biologic therapy that can be marketed when the original’s patent expires – can make these therapies available at reduced costs. This makes biosimilars very attractive to financially overburdened health care systems (and to patients). Dr. Cecil Nick has worked for more three decades in global clinical development and regulatory affairs, and will chair DIA’s Biosimilars 2017 Conference. “I think this is going to be the most exciting biosimilars event ever,” he explains in this Global Forum conference preview. “It’s not just a question of tracking through issues that the audience has heard many, many times before, but really delving into the really critical issues that are evolving as biosimilars are developing, as we’re gaining more experience, and as the regulations are evolving.”
20 episodes
Share
